MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318072 | Name: Isoniazid
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Isoniazid is an antibiotic used as a first-line agent for the prevention and treatment of both latent and active tuberculosis. It is effective against mycobacteria, particularly Mycobacterium tuberculosis. It is also active against some atypical types of mycobacteria, such as M. kansasii and M. xenopi.

Chemical Structure

Isoniazid
Isoniazid
CAS#54-85-3

Theoretical Analysis

MedKoo Cat#: 318072

Name: Isoniazid

CAS#: 54-85-3

Chemical Formula: C6H7N3O

Exact Mass: 137.0589

Molecular Weight: 137.14

Elemental Analysis: C, 52.55; H, 5.14; N, 30.64; O, 11.67

Price and Availability

Size Price Availability Quantity
10g USD 250.00 2 Weeks
25g USD 400.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Isoniazid, Isonicotinylhydrazide, Hydra, Hyzyd, Isovit, Nydrazid
IUPAC/Chemical Name
pyridine-4-carbohydrazide
InChi Key
QRXWMOHMRWLFEY-UHFFFAOYSA-N
InChi Code
InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)
SMILES Code
O=C(C1=CC=NC=C1)NN
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Isoniazid (INH) is a prodrug and must be activated by a bacterial catalase-peroxidase enzyme KatG. Isoniazid is bactericidal to rapidly dividing mycobacteria and has anti-tuberculostatic activity.
In vitro activity:
The cell viability decreased with the increase of INH (isoniazid) concentration in Huh7 cells, but the cell viability decreased slightly in HepG2 cells due to the agglomeration growth (Figures 3C,D). In addition, qRT-PCR results revealed that INH treatment increased endogenous RNA of NAT2 gene (Figures 3E,F). However, in terms of NAT2 protein level, it was increased only in Huh7 cells after INH treatment, while this phenomenon was not obvious in HepG2 cells (Figures 3G,H). Reference: Front Mol Biosci. 2021 Nov 23;8:752072. https://pubmed.ncbi.nlm.nih.gov/34888351/
In vivo activity:
These findings indicate that QSA may play a hepatoprotective effect in INH (isoniazid)-induced zebrafish liver injury through the PI3K-AKT signalling pathway, which further validated the network pharmacology and molecular docking results that quercetin is an important component in HDW against INH-induced liver injury. Reference: Drug Des Devel Ther. 2022 Jun 27;16:1995-2015. https://pubmed.ncbi.nlm.nih.gov/35783199/
Solvent mg/mL mM
Solubility
DMF 0.5 3.65
DMSO 26.0 189.59
Ethanol 23.0 196.88
PBS (pH 7.2) 1.0 7.29
Water 30.2 219.96
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 137.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Li X, Zhang H, Xu L, Jin Y, Luo J, Li C, Zhao K, Zheng Y, Yu D, Zhao Y. miR-15a-3p Protects Against Isoniazid-Induced Liver Injury via Suppressing N-Acetyltransferase 2 Expression. Front Mol Biosci. 2021 Nov 23;8:752072. doi: 10.3389/fmolb.2021.752072. PMID: 34888351; PMCID: PMC8651391. 2. Qu X, Zhang Y, Zhang S, Zhai J, Gao H, Tao L, Song Y. Dysregulation of BSEP and MRP2 May Play an Important Role in Isoniazid-Induced Liver Injury via the SIRT1/FXR Pathway in Rats and HepG2 Cells. Biol Pharm Bull. 2018;41(8):1211-1218. doi: 10.1248/bpb.b18-00028. PMID: 30068870. 3. Wang X, Zhao J, Zhang R, Liu X, Ma C, Cao G, Wei Y, Yang P. Protective Effect of Hedyotis diffusa Willd. Ethanol Extract on Isoniazid-Induced Liver Injury in the Zebrafish Model. Drug Des Devel Ther. 2022 Jun 27;16:1995-2015. doi: 10.2147/DDDT.S358498. PMID: 35783199; PMCID: PMC9249440. 4. Liu K, Li F, Lu J, Gao Z, Klaassen CD, Ma X. Role of CYP3A in isoniazid metabolism in vivo. Drug Metab Pharmacokinet. 2014;29(2):219-22. doi: 10.2133/dmpk.dmpk-13-nt-089. Epub 2013 Oct 29. PMID: 24172716; PMCID: PMC4004657.
In vitro protocol:
1. Li X, Zhang H, Xu L, Jin Y, Luo J, Li C, Zhao K, Zheng Y, Yu D, Zhao Y. miR-15a-3p Protects Against Isoniazid-Induced Liver Injury via Suppressing N-Acetyltransferase 2 Expression. Front Mol Biosci. 2021 Nov 23;8:752072. doi: 10.3389/fmolb.2021.752072. PMID: 34888351; PMCID: PMC8651391. 2. Qu X, Zhang Y, Zhang S, Zhai J, Gao H, Tao L, Song Y. Dysregulation of BSEP and MRP2 May Play an Important Role in Isoniazid-Induced Liver Injury via the SIRT1/FXR Pathway in Rats and HepG2 Cells. Biol Pharm Bull. 2018;41(8):1211-1218. doi: 10.1248/bpb.b18-00028. PMID: 30068870.
In vivo protocol:
1. Wang X, Zhao J, Zhang R, Liu X, Ma C, Cao G, Wei Y, Yang P. Protective Effect of Hedyotis diffusa Willd. Ethanol Extract on Isoniazid-Induced Liver Injury in the Zebrafish Model. Drug Des Devel Ther. 2022 Jun 27;16:1995-2015. doi: 10.2147/DDDT.S358498. PMID: 35783199; PMCID: PMC9249440. 2. Liu K, Li F, Lu J, Gao Z, Klaassen CD, Ma X. Role of CYP3A in isoniazid metabolism in vivo. Drug Metab Pharmacokinet. 2014;29(2):219-22. doi: 10.2133/dmpk.dmpk-13-nt-089. Epub 2013 Oct 29. PMID: 24172716; PMCID: PMC4004657.
1: Bateman DN, Page CB. Antidotes to coumarins, isoniazid, methotrexate and thyroxine, toxins that work via metabolic processes. Br J Clin Pharmacol. 2016 Mar;81(3):437-45. doi: 10.1111/bcp.12736. Epub 2015 Oct 24. Review. PubMed PMID: 26255881. 2: Metushi IG, Uetrecht J, Phillips E. Mechanism of isoniazid-induced hepatotoxicity: then and now. Br J Clin Pharmacol. 2016 Jan 15. doi: 10.1111/bcp.12885. [Epub ahead of print] Review. PubMed PMID: 26773235. 3: Harries AD, Lawn SD, Suthar AB, Granich R. Benefits of combined preventive therapy with co-trimoxazole and isoniazid in adults living with HIV: time to consider a fixed-dose, single tablet coformulation. Lancet Infect Dis. 2015 Dec;15(12):1492-6. doi: 10.1016/S1473-3099(15)00242-X. Epub 2015 Oct 27. Review. PubMed PMID: 26515525. 4: Hassan HM, Guo HL, Yousef BA, Luyong Z, Zhenzhou J. Hepatotoxicity mechanisms of isoniazid: A mini-review. J Appl Toxicol. 2015 Dec;35(12):1427-32. doi: 10.1002/jat.3175. Epub 2015 Jun 10. Review. PubMed PMID: 26095833. 5: Yuen CM, Jenkins HE, Rodriguez CA, Keshavjee S, Becerra MC. Global and Regional Burden of Isoniazid-Resistant Tuberculosis. Pediatrics. 2015 Jul;136(1):e50-9. doi: 10.1542/peds.2015-0172. Epub 2015 Jun 1. Review. PubMed PMID: 26034243; PubMed Central PMCID: PMC4485010. 6: Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virol. 2015 May 12;4(2):105-12. doi: 10.5501/wjv.v4.i2.105. Review. PubMed PMID: 25964875; PubMed Central PMCID: PMC4419114. 7: Briggs MA, Emerson C, Modi S, Taylor NK, Date A. Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature. J Acquir Immune Defic Syndr. 2015 Apr 15;68 Suppl 3:S297-305. doi: 10.1097/QAI.0000000000000497. Review. PubMed PMID: 25768869. 8: Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review. PLoS One. 2015 Mar 23;10(3):e0119628. doi: 10.1371/journal.pone.0119628. eCollection 2015. Review. PubMed PMID: 25799046; PubMed Central PMCID: PMC4370653. 9: Coban AY, Deveci A, Sunter AT, Palomino JC, Martin A. Resazurin microtiter assay for isoniazid, rifampicin, ethambutol and streptomycin resistance detection in Mycobacterium tuberculosis: Updated meta-analysis. Int J Mycobacteriol. 2014 Dec;3(4):230-41. doi: 10.1016/j.ijmyco.2014.09.002. Epub 2014 Sep 29. Review. PubMed PMID: 26786621. 10: Recommendation on 36 Months Isoniazid Preventive Therapy to Adults and Adolescents Living with HIV in Resource-Constrained and High TB- and HIV-Prevalence Settings: 2015 Update. Geneva: World Health Organization; 2015. PubMed PMID: 26203486. 11: Ameeruddin NU, Luke Elizabeth H. Impact of isoniazid resistance on virulence of global and south Indian clinical isolates of Mycobacterium tuberculosis. Tuberculosis (Edinb). 2014 Dec;94(6):557-63. doi: 10.1016/j.tube.2014.08.011. Epub 2014 Sep 6. Review. PubMed PMID: 25270728. 12: Nourbakhsh B, Stüve O. Isoniazid in autoimmunity: a trigger for multiple sclerosis? Ther Adv Neurol Disord. 2014 Sep;7(5):253-6. doi: 10.1177/1756285614540361. Review. PubMed PMID: 25342979; PubMed Central PMCID: PMC4206619. 13: Vilchèze C, Jacobs WR Jr. Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities. Microbiol Spectr. 2014 Aug;2(4):MGM2-0014-2013. doi: 10.1128/microbiolspec.MGM2-0014-2013. Review. PubMed PMID: 26104204. 14: Adams LV, Talbot EA, Odato K, Blunt H, Steingart KR. Interventions to improve delivery of isoniazid preventive therapy: an overview of systematic reviews. BMC Infect Dis. 2014 May 21;14:281. doi: 10.1186/1471-2334-14-281. Review. PubMed PMID: 24886159; PubMed Central PMCID: PMC4038070. 15: Boelsterli UA, Lee KK. Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress. J Gastroenterol Hepatol. 2014 Apr;29(4):678-87. Review. PubMed PMID: 24783247. 16: Wood R, Bekker LG. Isoniazid preventive therapy for tuberculosis in South Africa: an assessment of the local evidence base. S Afr Med J. 2014 Mar;104(3):174-7. Review. PubMed PMID: 24897817. 17: Makanjuola T, Taddese HB, Booth A. Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: a systematic review of qualitative data. PLoS One. 2014 Feb 3;9(2):e87166. doi: 10.1371/journal.pone.0087166. eCollection 2014. Review. PubMed PMID: 24498298; PubMed Central PMCID: PMC3911939. 18: Martins F, Ventura C, Santos S, Viveiros M. QSAR based design of new antitubercular compounds: improved isoniazid derivatives against multidrug-resistant TB. Curr Pharm Des. 2014;20(27):4427-54. Review. PubMed PMID: 24245762. 19: Coban AY, Deveci A, Sunter AT, Martin A. Nitrate reductase assay for rapid detection of isoniazid, rifampin, ethambutol, and streptomycin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Clin Microbiol. 2014 Jan;52(1):15-9. doi: 10.1128/JCM.01990-13. Epub 2013 Oct 16. Review. PubMed PMID: 24131684; PubMed Central PMCID: PMC3911439. 20: Schaaf HS, Cotton MF, Boon GP, Jeena PM. Isoniazid preventive therapy in HIV-infected and -uninfected children (0 - 14 years). S Afr Med J. 2013 Sep 4;103(10):714-5. doi: 10.7196/samj.7189. Review. PubMed PMID: 24079619.